Table 2 Univariate analysis of prognostic factors of survival in patients with TE-SCC with CLM
5-year | Median survival | ||||
|---|---|---|---|---|---|
Variable | All (%) | Survival rate (%) | (Months) | χ2value | P- value |
Patients | 547 (100) | 27.7 | |||
Sex | 8.323 | 0.004 | |||
Male | 406 (74.2) | 24.6 | 24.8 | ||
Female | 141 (25.8) | 37.0 | 39.5 | ||
Age (years) | 0.225 | 0.635 | |||
<60 | 335 (61.2) | 27.8 | 25.9 | ||
≥60 | 212 (38.8) | 27.1 | 31.5 | ||
Thoracic tumor location | 0.456 | 0.796 | |||
Upper | 121 (22.1) | 31.7 | 29.2 | ||
Middle | 403 (73.7) | 26.6 | 26.8 | ||
Lower | 23 (4.2) | 23.3 | 25.5 | ||
Differentiation | 1.623 | 0.444 | |||
Low | 118 (21.6) | 23.4 | 24.1 | ||
Intermediate | 349 (63.8) | 29.1 | 27.8 | ||
High | 80 (14.6) | 28.6 | 28.3 | ||
Tumor length (cm) | 7.638 | 0.006 | |||
≤5 | 283 (51.7) | 31.7 | 32.0 | ||
>5 | 264 (48.3) | 23.4 | 23.6 | ||
pT stage | 20.517 | <0.0001 | |||
pT1 | 16 (2.9) | 86.7 | 53.6 | ||
pT2 | 84 (15.4) | 41.6 | 43.4 | ||
pT3 | 386 (70.6) | 23.1 | 26.4 | ||
pT4 | 61 (11.2) | 23.2 | 22.5 | ||
Number of nodal metastases | 63.872 | <0.0001 | |||
1-2 | 226 (41.3) | 43.3 | 49.7 | ||
3-6 | 221 (40.4) | 20.3 | 23.5 | ||
≥7 | 100 (18.3) | 9.9 | 16.7 | ||
Number of fields with positive lymph nodesa | 55.313 | <0.0001 | |||
1 field | 191 (34.9) | 43.0 | 43.3 | ||
2 fields | 214 (39.1) | 25.5 | 29.2 | ||
3 fields | 142 (26.0) | 10.2 | 19.3 | ||
Treatment program | 18.145 | <0.0001 | |||
Surgery only | 296 (54.1) | 21.3 | 21.9 | ||
Surgery + radiation | 251 (45.9) | 34.2 | 35.4 | ||